Opioid use and patient outcomes in an Australian hip and knee arthroplasty cohort

Phil Huang,*† Jack Brownrigg,‡ Justin Roe,*¶¶ David Carmody,*§ Leo Pinczewski ©,*†† Benjamin Gooden,*§ Matthew Lyons,*§ Lucy Salmon ©,*†† Ka Martina ©,*†† Joanna Crighton† and Michael O’Sullivan*§

*North Sydney Orthopaedic Research Group, Sydney, New South Wales, Australia
†Orthopaedic Services, The Mater Hospital, Sydney, New South Wales, Australia
‡School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
§North Sydney Orthopaedic and Sports Medicine Centre, Sydney, New South Wales, Australia and
¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©North Sydney Orthopaedic and Sports Medicine Centre, Sydney, New South Wales, Australia
¶¶North Sydney Orthopaedic and Sports Medicine Centre, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
©¶¶School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia
©¶¶School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia

Key words
arthroplasty, hip, knee, opioids, pain control.

Abstract
Background: To determine the prevalence of opioid use in Australian hip (THA) or knee (TKA) cohort, and its association with outcomes.
Methods: About 837 primary THA or TKA subjects prospectively completed Oxford Scores, and Knee or Hip Osteoarthritis Outcomes Score(KOOS/HOOS) and opioid use in the previous week before arthroplasty. Subjects repeated the baseline survey at 6 months, with additional questions regarding satisfaction.
Results: Opioid use was reported by 19% preoperatively and 7% at 6 months. Opioid use was 46% at 6 weeks and 10% at 6 months after TKR, and 16% at 6 weeks and 4% at 6 months after THR. Preoperative opioid use was associated with back pain(OR 2.2, P = 0.006), anxiety or depression(OR 1.8, P = 0.001) and Oxford knee scores <30(OR 5.6, P = 0.021) in TKA subjects, and females in THA subjects(OR 1.7, P = 0.04). There was no difference between preoperative opioid users and non-users for satisfaction, or KOOS or HOOS scores at 6 months. 77% of patients taking opioids before surgery had ceased by 6 months, and 3% of preoperative non users reported opioid use at 6 months. Opioid use at 6 months was associated with preoperative use (OR 6.6–14.7, P < 0.001), and lower 6 month oxford scores (OR 4.4–83.6, P < 0.01).
Conclusion: One in five used opioids before arthroplasty. Pre-operative opioid use was the strongest risk factor for opioid use at 6 months, increasing odds 7–15 times. Prolonged opioid use was rarely observed in the opioid naïve (<5% TKA and 1% THA). Preoperative opioid use was not associated with inferior outcomes or satisfaction.

Introduction
The ‘opioid epidemic’ is a worldwide affliction with 110 000 deaths attributed to opioid use in 2017, an increase by 77% over a decade. In the United States (US), the economic burden of opioid use disorder was calculated at $1.02 trillion in 2017, and an estimated 9.4 million people misused prescription opioids in 2019. In 2014–2016 Australia had the eighth highest opioid consumption in a comparison of 167 countries, and opioid related deaths have nearly doubled over the last 10 years. The use of pharmaceutical opioids is particularly high in the elderly, with 44% of opioid prescriptions dispensed in those aged 65 and more. Pain is a common and disabling feature of hip and knee osteoarthritis. Whilst opioids are commonly prescribed, their use for osteoarthritis is not recommended, and do not provide any benefit over ibuprofen or paracetamol to manage arthritic pain. Opioid use in the arthroplasty population in increasing, and has been associated with adverse outcomes with respect to length of hospital stay, patient reported outcomes, mortality and morbidity, revision
surgery, and infection, knee stiffness, and prolonged post-operative opioid use compared to non-opioid users.

There is considerable variation in rates of opioid use across arthroplasty populations, with ranges from 16% to 90% before, and 11%–41% >3 months after arthroplasty. Most of these epidemiological studies arise from populations in the US, where there are much higher rates of opioid use, compared to Australasia and Europe. The rate of opioid use in Australia has been reported in exclusively veteran and uninsured cohorts, and varies from 16% to 46% preoperatively, and 30%–36% >3 months after arthroplasty, with elevated rates observed in veterans. The aim of this study was to determine the prevalence of opioid use before and after THA and TKA in a privately insured Australian population and examine its association with patient factors and patient reported outcomes.

Patients and methods

Study design and participants

The prospective cohort study was performed at the North Sydney Orthopaedic and Sports Medicine Centre, Sydney, Australia. Eligible patients were undergoing primary elective THA or TKA under the care of one of seven experienced surgeons between May 2019 and October 2020 at a single hospital. The study was approved by St Vincent’s Human Research Ethics Committee, Darlinghurststand all subjects provided informed consent. Subjects (n = 864) completed a series of patient reported outcomes measures (PROMs) preoperatively, at 6 weeks and 6 months after surgery. The routine data collection includes numerous demographic and operative variables. Subjects were excluded in the case of incomplete baseline PROMs (n = 23), death during the follow up (n = 1), and revision arthroplasty surgery (n = 3). The remaining 837 subjects formed the study group.

Opioid use

Subjects were surveyed regarding their consumption of any opioids within the previous 7 days before surgery, at 6 weeks and at 6 months following surgery with sufficient detail to determine a daily morphine equivalent dose (MED). If opioid consumption was inconsistent then the maximum daily MED was used. Opioid use was defined as any opioid consumption within the previous 7 days for any indication. Opioid use was further categorized as opioid-naive (0 mg MED), opioid exposed (<60 mg MED) or opioid tolerant (>60 mg MED).

6 week review

At 6 weeks subjects reported average pain in the last 24 h on a visual analog scale (VAS), analgesia and opioid use. Complications within 6 weeks were documented.

Patient reported outcome measures

Preoperative and 6 month PROMs included the disease specific short form HOOS or KOOS JR, and Oxford Knee or Hip Score. The EQ5D was selected as a widely used generic measure of health status, measuring mobility, self-care, activity, pain and anxiety. Satisfaction was assessed after surgery with four additional questions: would they have the same surgery again under the same circumstances (Yes/No/Unsure), grading satisfaction with the results of surgery on 5-point Likert scale from ‘very disappointed’ to ‘very satisfied’, and grading ‘overall, how the problems are now with your hip or knee on which you had surgery, compared to before you had your operation?’ (much better/a little better/about the same/a little worse/much worse). The preoperative and 6 month survey was completed online using REDCap electronic data capture tools, or using a paper copy if preferred.

Statistical analysis

Data analysis was performed using SPSS data analysis software version 27. Frequencies were compared between groups using chi square tests, and means compared with t-tests. Missing data was not imputed and complete case analysis was used for regression models. Opioid use was dichotomised as any or none for the regression model. Univariate logistic regression analysis of opioid use was analysed for TKA and THA groups separately for the factors of gender, age <55, obesity (BMI 30 or more), any anxiety or depression on EQSD, discharge destination (home or inpatient rehabilitation), Oxford score <30, back pain and preoperative opioid use. Significant factors were entered into multivariate logistic model in a forward fashion. Odds Ratios for each factor with 95% confidence intervals and statistical p value was determined.

Results

About 837 subjects underwent primary THA or TKA consented to participate and completed preoperative PROMs. Of these, 792 completed PROMS at 6 weeks and 709 completed PROMs at 6 months (Fig. 1). The demographics and operative measures for the TKA and THA cohort is shown in Table 1.

Opioid use in THA and TKA cohorts

Opioid use was reported by 154 (18%) before surgery, 236 (28%) at 6 weeks and 48 (7%) at 6 months. The prevalence of opioid use at each review is shown for TKA and THA subjects in Figure 2. The prevalence of opioid use was equivalent between THA and TKA preoperatively, but three times higher in the TKA subjects at 6 weeks and 2.5 times higher in the TKA subjects at 6 months. Opioid use was recorded with insufficient detail to determine MED in 17 subjects before surgery and in six subjects at 6 weeks. The mean MED in opioid users was 24.7 mg (range 1-263) preoperatively, 23.7 mg (range 1-203) at 6 weeks and 20.0 mg (range 2-111) at 6 months. There was no significant difference in mean MED between THA and TKA subjects preoperatively (P = 0.933), at 6 weeks (P = 0.402), or 6 months (P = 0.999). The number of subjects taking opioids graded according to MED dose for THA and TKA subjects is shown in Table 2.
Opioid user to non-user
The change in opioid use is shown in Figure 3. In the TKA cohort 67 (17%) were taking opioids preoperatively, of these 68% had ceased opioids at 6 months. Of the 328 opioid naïve TKA subjects, 5% reported opioid use at 6 months. In the THA cohort 87 (20%) were taking opioids preoperatively and 83% had ceased opioids at 6 months. Of the 355 opioid naïve THA subjects, 1% reported opioid use at 6 months.

Regression analysis of opioid use
The logistic multivariate regression analysis of opioid use is shown for TKA subjects and THA subjects in Tables 3–5.

Outcomes by baseline opioid use
Preoperative TKA opioid users had a lower preoperative mean KOOS Score (39 versus 51, \( P = 0.001 \)), Oxford Score (17 versus 24, \( P = 0.001 \)), and EQ5D General Health Score (60 versus 68, \( P = 0.004 \)), than non-users. Preoperative THA opioid users had a lower preoperative mean HOOS Score (48 versus 57, \( P = 0.001 \)), Oxford Score (18 versus 24, \( P = 0.001 \)), and EQ5D General Health Score (57 versus 68, \( P = 0.001 \)), than non-users. There was no difference in mean acute length of stay between opioid users and non-users for TKA (5.3 versus 5.2, \( P = 0.83 \)) or THA (4.5 versus 4.7, \( P = 0.14 \)). There was no difference in prevalence of readmission within 30 days between opioid users and non-users for TKA (2% versus 2% \( P = 0.939 \)) or THA (1% versus 2%, \( P = 0.753 \)). Six months outcomes are compared between preoperative opioid users and opioid naïve for TKA in Table 6 and THA in Table 7.

Discussion
In this Australian cohort 19% reported opioid use before arthroplasty. After TKA opioid use was 46% at 6 weeks and 10% at 6 months, and after THA opioid use was 16% at 6 weeks and 4% at 6 months. Preoperative opioid use did not diminish the postoperative improvement nor the absolute pain and function scores, or rates of satisfaction. Preoperative opioid use in TKA subjects was associated with back pain, anxiety or depression and low Oxford knee scores. Preoperative opioid use in THA subjects was associated with females. Of those taking opioids before surgery 77% had ceased at 6 months after arthroplasty, and only 3% of opioid naïve subjects reported opioid use at 6 months. Opioid use at 6 months was associated with preoperative opioid use, and lower 6 month Oxford scores for both THA and TKA cohorts.
which may explain the differences observed. This is supported by reports that opioid users who weaned opioid use by 50% experienced similar improvements to their opioid naïve counterparts. A recent systematic review and meta-analysis involving 7356 patients concluded that opioid users had worse absolute PROM scores, but similar relative change in scores when compared to opioid naïve patients. We observed a greater improvement in opioid users, resulting in equivalent PROM between opioid users and non-users at 6 months. If opioid use prior to arthroplasty is of a low dosage then at least equivalent PROMs, and rates of satisfaction to non-users may be achieved.

Pre-operative opioid use has an established effect on sustained post-operative opioid use, and our study further supports this finding. Pre-operative opioid use was the strongest risk factor for opioid consumption at 6 months, increasing the odds by 7–15 times for TKA and THA respectively, with a greater influence than poor Oxford Scores. A recent systematic review reported post-operative opioid use to be 35%–68% in THA and TKA patients who took opioids pre-operatively and 0.6%–4% in patients who were opioid naïve. In our study preoperative opioid users continued use at 6 months in 15%–31% of TKA and THA subjects respectively, compared to preoperative non users who used opioids at 6 months in only 6% of TKA and 1% of THA subjects. To minimize prolonged opioid use most effectively clinicians need to address it before arthroplasty, weaning to the lowest possible dose.

As opioids are prescribed by internal medicine or primary care providers in 60%–70% of arthroplasty cases, careful coordination and communication between orthopaedic surgeons, patients and other primary care providers as to expectations for opioid use may be paramount to successfully managing prolonged opioid use in this population.

Opioid use before and after arthroplasty observed in this study were considerably lower than many previous studies, but considerable geographical variation is commonly reported. In the largest series of a US cohort from 2010 to 2014 Jin examined 473 781 subjects and found 31% of TKR and 41% of THR subjects reported opioid use in the month before arthroplasty. Outside the US relatively consistent rates of opioid use of 22%–28% preoperatively and 13%–16% at 3–6 months after surgery has been reported in New Zealand, and Scandinavia. The lowest rates were seen in Finland with preoperative opioid use of 9%–14% in TKA and THA patients respectively, and 7% at 9–12 months after surgery.

### Table 2: Opioid use in TKA and THA subjects graded by morphine equivalent daily dose

| Preoperative opioid use | Knee arthroplasty | Hip arthroplasty | P |
|-------------------------|------------------|-----------------|---|
| Naïve (MED = 0 mg)      | 328 (84%)        | 431             |    |
| Exposed (MED < 60 mg)   | 54 (14%)         | 64 (15%)        |    |
| Tolerant (MED ≥ 60 mg)  | 7 (2%)           | 13 (3%)         |    |
| 6 week (n)              | 362              | 425             |    |
| Naïve (MED = 0 mg)      | 196 (54%)        | 361 (85%)       |    |
| Exposed (MED < 60 mg)   | 151 (42%)        | 59 (14%)        |    |
| Tolerant (MED ≥ 60 mg)  | 15 (4%)          | 5 (1%)          |    |
| 6 month (n)             | 338              | 371             |    |
| Naïve (MED = 0 mg)      | 306 (90%)        | 355 (96%)       |    |
| Exposed (MED < 60 mg)   | 29 (9%)          | 16 (4%)         |    |
| Tolerant (MED ≥ 60 mg)  | 3 (1%)           | 0 (0%)          |    |

**Denotes statistically significant factors.

![Fig. 3. Change in incidence of any opioid use from preoperative to 6 months review.](image)

This study is the largest to assess the relationship between opioid use and PROMS in the last decade, the first in a cohort outside the US, and the first to include measures of satisfaction for THA and TKA subjects. When compared to non-opioid users, those taking opioids before surgery had lower baseline disease specific, general health and depression/anxiety scores. Opioid users experienced a significantly greater improvement after surgery, compared to opioid naïve subjects so that their pain and function outcomes were equivalent at 6 months, as were their rates of satisfaction. This contrasts with other studies that have reported lower levels of improvement in pain score in opioid users compared to opioid naïve subjects. Our cohort had considerably lower proportion taking >60 mg MEDD and lower mean MED doses than other studies by more than 50%, which may explain the differences observed. This is supported by reports that opioid users who weaned opioid use by 50% experienced similar improvements to their opioid naïve counterparts. A recent systematic review and meta-analysis involving 7356 patients concluded that opioid users had worse absolute PROM scores, but similar relative change in scores when compared to opioid naïve patients. We observed a greater improvement in opioid users, resulting in equivalent PROM between opioid users and non-users at 6 months. If opioid use prior to arthroplasty is of a low dosage then at least equivalent PROMs, and rates of satisfaction to non-users may be achieved.

Pre-operative opioid use has an established effect on sustained post-operative opioid use, and our study further supports this finding. Pre-operative opioid use was the strongest risk factor for opioid consumption at 6 months, increasing the odds by 7–15 times for TKA and THA respectively, with a greater influence than poor Oxford Scores. A recent systematic review reported post-operative opioid use to be 35%–68% in THA and TKA patients who took opioids pre-operatively and 0.6%–4% in patients who were opioid naïve. In our study preoperative opioid users continued use at 6 months in 15%–31% of TKA and THA subjects respectively, compared to preoperative non users who used opioids at 6 months in only 6% of TKA and 1% of THA subjects. To minimize prolonged opioid use most effectively clinicians need to address it before arthroplasty, weaning to the lowest possible dose. As opioids are prescribed by internal medicine or primary care providers in 60%–70% of arthroplasty cases, careful coordination and communication between orthopaedic surgeons, patients and other primary care providers as to expectations for opioid use may be paramount to successfully managing prolonged opioid use in this population.

Opioid use before and after arthroplasty observed in this study were considerably lower than many previous studies, but considerable geographical variation is commonly reported. In the largest series of a US cohort from 2010 to 2014 Jin examined 473 781 subjects and found 31% of TKR and 41% of THR subjects reported opioid use in the month before arthroplasty. Outside the US relatively consistent rates of opioid use of 22%–28% preoperatively and 13%–16% at 3–6 months after surgery has been reported in New Zealand, and Scandinavia. The lowest rates were seen in Finland with preoperative opioid use of 9%–14% in TKA and THA patients respectively, and 7% at 9–12 months after surgery.

### Table 3: Multivariate logistic regression of preoperative opioid use

| Preoperative opioid use | Total knee arthroplasty | P | Total hip arthroplasty | P |
|-------------------------|-------------------------|---|------------------------|---|
| No opioid use (N = 328) | Any opioid use (N = 67) | OR | 95%CI | 0.447 | Any opioid use (N = 355) | OR | 95%CI | 0.083 |
| Female                  | 158 (48%)               | 40 (60%) | 1.2 | 0.7–2.2 | 183 (52%) | 55 (63%) | 1.7 | 1.0–2.8 | 0.041** |
| Obesity (BMI 30 or more) | 153 (47%)               | 42 (67%) | 1.7 | 0.3–3.0 | 110 (31%) | 36 (41%) | 1.5 | 0.9–2.6 | 0.095 |
| Back Pain VAS 4 or more | 97 (30%)                | 38 (58%) | 2.2 | 1.3–3.9 | 160 (46%) | 44 (51%) | 1.0 | 0.6–1.6 | 0.918 |
| Anxiety or Depression   | 147 (45%)               | 51 (76%) | 2.8 | 1.6–5.2 | 163 (48%) | 55 (63%) | 2.0 | 0.9–4.1 | 0.075 |
| Preoperative Oxford Score < 30 | 250 (76%) | 65 (98%) | 5.6 | 1.3–24.0 | 264 (74%) | 77 (89%) | 2.1 | 0.9–5.0 | 0.088 |

Abbreviations: CI, confidence interval; OR, odds ratio.

**Denotes statistically significant factors.
These rates are more than double the rate of our previously published study. Naylor et al. examined 521 THA or TKA subjects in an Australian public hospital cohort of whom 16% reported regular opioid use before, and 30% at 3 months after surgery. In our cohort opioid use within the previous week was reported by 18% before surgery, 28% at 6 weeks and only 7% at 6 months. Differences in opioid use may be influenced by the healthcare setting.\(^1\) Our subjects were all privately insured, a group different to the exclusively veteran sample. Naylor et al. cohort, and similar to US based studies, but may be influenced by the window of 7 days rather than 30 days leading to opioid use, which may explain the variation. However observed differences may also be related to our shorter reporting window of 7 days rather than 30–90 days, or other inconsistencies in the definition of opioid use, whether it was determined from prescription data, dispensing records or patient reported recall, methods which all arguably have inherent flaws. These inconsistencies hamper comparisons universally, and have been recently addressed by a consensus group who recommend standardized definitions on univariate analysis.

### Table 4: Multivariate logistic regression of 6 week opioid use

| 6 week opioid use | Total knee arthroplasty | Total hip arthroplasty |
|-------------------|-------------------------|------------------------|
| **No opioid use** | **Any opioid use** | **P** | **No opioid use** | **Any opioid use** | **P** |
| N = 196 | N = 170 | OR | 95%CI | P | N = 361 | OR | 95%CI | P |
| Preoperative opioid use | 20 (10%) | 40 (24%) | 3.5 | 1.6–7.5 | 0.004** | 53 (15%) | 28 (42%) | 14.7 | 4.2–50.7 | 0.001** |
| Joint pain at 6 weeks VAS 5 or more | 54 (28%) | 66 (39%) | 4.0 | 2.0–7.9 | 0.001** | 160 (45%) | 38 (59%) | 8.5 | 2.9–25.0 | 0.001** |
| Attended inpatient rehabilitation | 79 (45%) | 85 (59%) | 1.9 | 1.2–3.2 | 0.012** | 139 (40%) | 43 (68%) | 2.4 | 1.3–4.5 | 0.008** |
| Preoperative back pain VAS 4 or more | 54 (28%) | 66 (39%) | 1.1 | 0.6–1.8 | 0.860 | 160 (45%) | 38 (59%) | 1.5 | 0.8–2.9 | 0.205 |
| Preoperative anxiety or depression | 93 (47%) | 91 (54%) | 1.1 | 0.4–3.2 | 0.298 | 165 (46%) | 42 (64%) | 1.4 | 0.7–2.7 | 0.222 |
| Preoperative Oxford Score < 30 | 142 (72%) | 147 (87%) | 1.3 | 0.7–2.5 | 0.411 | 270 (75%) | 57 (86%) | 1.1 | 0.5–2.6 | 0.870 |

### Table 5: Multivariate logistic regression of 6 month opioid use

| 6 month opioid use | Total knee arthroplasty | Total hip arthroplasty |
|-------------------|-------------------------|------------------------|
| **No opioid use** | **Any opioid use** | **P** | **No opioid use** | **Any opioid use** | **P** |
| N = 306 | N = 32 | OR | 95%CI | P | N = 355 | OR | 95%CI | P |
| Preoperative opioid use | 36 (12%) | 17 (53%) | 6.6 | 2.7–16.1 | 0.004** | 60 (17%) | 12 (75%) | 14.7 | 4.2–50.7 | 0.001* |
| 6 month Oxford Score < 30 | 17 (6%) | 8 (25%) | 4.4 | 1.4–13.8 | 0.010** | 13 (4%) | 5 (31%) | 8.6 | 2.0–36.2 | 0.003* |
| Preoperative back pain VAS 4 or more | 98 (32%) | 17 (57%) | 1.3 | 0.5–3.2 | 0.505 | 163 (46%) | 11 (69%) | 2.1 | 0.6–7.3 | 0.234 |
| Preoperative anxiety or depression | 142 (46%) | 25 (76%) | 1.9 | 0.7–5.0 | 0.203 | 172 (49%) | 10 (63%) | 1.4 | 0.4–4.8 | 0.625 |
| Preoperative Oxford Score < 30 | 239 (78%) | 30 (94%) | 1.4 | 0.3–6.5 | 0.706 | 272 (77%) | 13 (81%) | 0.4 | 0.1–1.9 | 0.245 |

### Table 6: 6 month patient reported outcomes for preoperative opioid non user and opioid users in knee arthroplasty participants

| 6 month PROMS | Preoperative opioid non user N = 285 | Preoperative opioid user N = 53 | Cohens d | P |
|---------------|--------------------------------------|---------------------------------|-----------|---|
| N             | 285                                  | 53                              |           |   |
| Opioid use at 6 months | 15 (5%)                              | 17 (32%)                        | –0.20     | 0.482 |
| KOOS score, mean | 78.7                                 | 77.2                            |           |   |
| KOOS score, mean Δ | 27.7                                 | 40.1                            | –0.71     | 0.901* |
| Oxford score, mean | 40.2                                 | 39.2                            | 0.14      | 0.362 |
| Oxford score, mean Δ | 15.9                                 | 23.1                            | –0.86     | 0.001* |
| Any depression or anxiety (%) | 52 (18%)                             | 17 (32%)                        | 0.022*    |   |
| Any problems with mobility (%) | 105 (37%)                            | 27 (51%)                        | 0.053     |   |
| EQ5D General Health Score, mean | 79.2                                 | 71.5                            | 0.40      | 0.013* |
| Satisfied with surgery | 264 (93%)                            | 46 (89%)                        | 0.308     |   |
| Same surgery again | 255 (90%)                            | 46 (89%)                        | 0.132     |   |
| Better after surgery | 272 (96%)                            | 50 (96%)                        | 0.303     |   |

*Denotes statistical significant difference between groups.

**Denotes statistically significant factors.
Regrettfully, our study was designed prior to publica-
tion of this recommendation so included questions regarding the
previous 7 days rather than the 90 days suggested by the group.
However it has been shown that opioid consumption is highest in
the month prior to surgery,\textsuperscript{19,33} which is when our baseline measure
was performed. Regardless we remain encouraged by the very low
rate of only 7% that continued opioid use, and <1% that would be
categorized as opioid tolerant beyond 6 months.

Discharge to an inpatient rehabilitation centre compared to
home was associated with greater odds of opioid use at 6 weeks
by a factor of 2×, even when controlled for pain scores and pre-
operative opioid use, and this is supported by others.\textsuperscript{33} By inter-
national standards Australians have a high rate of inpatient
rehabilitation use, in our cohort 51% of TKR and 45% of THR
subjects attended inpatient rehabilitation. Over the past 5 years
these rates are steadily decreasing, driven largely by the pressure
from health insurers and lack of evidence. Protocols have been
common in Australian inpatient rehabilitation units encouraging
routine opioid administration pre-emptively prior to rehabilita-
tion. A consistent message across all health providers that opioids
should only be considered in the acute post-operative phase
where possible, and in only presence of severe pain, rather than
an appropriate preventative measure for longer term postoperative
discomfort is warranted.

This study demonstrated one in five Australians used opioids
before arthroplasty. Pre-operative opioid use was the strongest
risk factor for opioid use at 6 months, increasing the odds by
7–15 times. Importantly, prolonged opioid use was rarely
observed in the opioid naïve cohort with less than 5% of TKA
and 1% of THA subjects, and persisting opioid tolerant users
represented <1% after arthroplasty. Preoperative opioid use
was not associated with inferior PROMS or satisfaction with
arthroplasty.

Table 7 6 month patient reported outcomes for preoperative opioid non user and opioid users in hip arthroplasty participants

| 6 month PROMS                  | Preoperative opioid non user N = 299 | Preoperative opioid user N = 72 | Cohens d | P    |
|--------------------------------|--------------------------------------|--------------------------------|----------|------|
| Opioid use at 6 months         | 4 (1%)                               | 12 (17%)                        | 0.001*   |      |
| HOOS score, mean               | 87.2                                 | 86.5                            | 0.05     | 0.716|
| HOOS score, mean Δ             | 30.4                                 | 38.2                            | −0.48    | 0.001*|
| Oxford score, mean             | 43.0                                 | 41.3                            | 0.27     | 0.047|
| Oxford score, mean Δ           | 18.6                                 | 23.3                            | −0.52    | 0.001*|
|Any depression or anxiety (%)   | 49 (16%)                             | 20 (28%)                        | 0.026*   |      |
|Any problems with mobility (%)  | 87 (29%)                             | 29 (40%)                        | 0.006    |      |
|EQ5D General Health Score, mean| 77.5                                 | 78.8                            | −0.06    | 0.659|

*Denotes statistical significant difference between groups.

Author contributions

Phil Huang: Conceptualization; data curation; methodology; writing – original draft; writing – review and editing. Jack Brownrigg:
Data curation; investigation; project administration; writing – review and editing. Justin Roe: Conceptualization; data curation;
funding acquisition; methodology; writing – review and editing. David Carmody: Conceptualization; data curation; methodology;
writing – review and editing. Leo Pinczewski: Conceptualization; data curation; methodology; writing – review and editing. Benja-
mim Gooden: Data curation; investigation; methodology; writing – review and editing. Matthew Lyons: Conceptualization; data
curation; methodology; writing – review and editing. Lucy Salmon: Data curation; formal analysis; funding acquisition; meth-
odology; writing – original draft; writing – review and editing. Ka Martina: Data curation; methodology; project administration;
writing – review and editing. Joanna Crighton: Data curation; methodology; project administration; writing – review and editing.

Michael O’Sullivan: Conceptualization; investigation; methodology; writing – review and editing.

Acknowledgements

This study was supported by the Friends of the Mater Foundation. Open access publishing facilitated by The University of Notre Dame Australia, as part of the Wiley - The University of Notre Dame Australia agreement via the Council of Australian University Librarians.
Conflict of interest

Phil Huang, Jack Brownrigg, Lucy J. Salmon, Ka Martina, Joanna Crichton, David Carmody, Benjamin Gooden have no relevant disclosures. Justin Roe is a paid consultant to Smith and Nephew and Pureplay Orthopaedics, holds shares in 360 Knee Systems, and receive research funding from Friends of the Mater and Corin. Leo Pinczewski holds stock and receives royalties from Australian Biotechnologies, and receives research support from Smith and Nephew. Matthew Christopher Lyons receive royalties from Depuy Synthes, is a paid consultant to Depuy Synthes, Corin, Zimmer Biomet, holds stock in NavBit and receives research support from Depuy Synthes. Michael O’Sullivan receives research support from Friends of the Mater and Corin.

References

1. Collaborators GCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017. Lancet 2018; 392: 1736–88.
2. Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States. 2017. Drug Alcohol Depend. 2021; 218: 108350.
3. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001). Rockville, MD, 2020. Available from URL https://www.samhsa.gov/data/
4. Welfare AloHa. Opioid Harm in Australia and Comparisons between Australia and Canada. Canberra: AIHW, 2018.
5. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 2019; 27: 1578–89.
6. Busse JW, Wang L, Kamaleldin M et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA 2018; 320: 2448–60.
7. Rozell J, Courtney P, Dattilo J, Wu C, Lee G. Preoperative opiate use independently predicts narcotic consumption and complications after Total joint arthroplasty. J. Arthroplasty 2017; 32: 2658–62.
8. Smith S, Bido J, Collins J, Yang H, Katz J, Losina E. Impact of preoperative opioid use on Total knee arthroplasty outcomes. J. Bone Joint Surg. Am. 2017; 99: 803–8.
9. Menendez ME, Ring D, Bateman BT. Preoperative opioid misuse is associated with increased morbidity and mortality after elective Orthopaedic surgery. Clin. Orthop. Relat. Res. 2015; 473: 2402–12.
10. Zywiel MG, Stroh DA, Lee SY, Bonutti PM, Mont MA. Chronic opioid use prior to total knee arthroplasty. J. Bone Joint Surg. Am. 2011; 93: 1988–93.
11. Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic use and Total knee arthroplasty. J. Arthroplasty 2018; 33: 113–8.
12. Shadbolt C, Schilling C, Inacio MC et al. Opioid use and Total joint replacement. Curr. Rheumatol. Rep. 2020; 22: 58.
13. Goplen CM, Verbeek W, Kang SH et al. Preoperative opioid use is associated with worse patient outcomes after Total joint arthroplasty: a systematic review and meta-analysis. BMC Musculoskelet. Disord. 2019; 20: 234.
14. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient factors associated with prolonged postoperative opioid use after Total knee arthroplasty. J. Arthroplasty 2018; 33: 2449–54.
15. Hansen C, Inacio M, Pratt N, Roughhead E, Graves S. Chronic use of opioids before and after Total knee arthroplasty: a retrospective cohort study. J. Arthroplasty 2017; 32: 811–7.
16. Inacio MCS, Hansen C, Pratt NL, Graves SE, Roughhead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open 2016; 6: e010664.
17. Jorgensen CC, Petersen M, Kehlet H, Aasvang EK. Analgesic consumption trajectories in 9875 patients 1 year after fast-track total hip or knee arthroplasty. Eur. J. Pain 2018; 22: 1428–38.
18. Blagstad T, Nordhus IH, Gronli J et al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics: results from a population of total hip arthroplasty patients. Pain 2016; 157: 643–51.
19. Jin Y, Solomon DH, Franklin PD et al. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthr. Cartil. 2019; 27: 1445–53.
20. Wilson R, Pryymachenko Y, Richard Audas J, Abbott H. Surgery oboCatooOi. Long-term opioid medication use before and after joint replacement surgery in New Zealand. N. Z. Med. J. 2019; 132: 104–7.
21. Naylor JM, Pavlovic N, Farrugia M et al. Associations between pre-surgical daily opioid use and short-term outcomes following knee or hip arthroplasty: a prospective, exploratory cohort study. BMC Musculoskelet. Disord. 2020; 21: 398.
22. Edwards DA, Hedrick TL, Jayaram J et al. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on perioperative Management of Patients on pre-operative opioid therapy. Anesthesia Analgesia. 2019; 129: 553–66.
23. Lyman S, Lee Y-Y, Franklin P, Li W, Cross M, Padgett D. Validation of the KOOS, JR: a short-form knee arthroplasty outcomes survey. Clin. Orthop. Relat. Res. 2016; 474: 1461–71.
24. Lyman S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What are the minimal and substantial improvements in the HOOS and KOOS and JR versions after total joint replacement? Clin. Orthop. Relat. Res. 2018; 476: 2432–41.
25. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total knee replacement. J. Bone Joint Surg. Br. 1998; 80: 63–9.
26. Dawson J, Fitzpatrick R, Carr A, Murray D. Questionnaire on the perceptions of patients about total hip replacement. J. Bone Joint Surg. Br. 1996; 78: 185–90.
27. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann. Med. 2001; 33: 337–43.
28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009; 42: 377–81.
29. Nguyen LC, Sing DC, Bozic KJ. Preoperative reduction of opioid use before Total joint arthroplasty. J. Arthroplasty 2016; 31: 282–7.
30. Kent ML, Hurley RW, Oderda GM et al. American Society for Enhanced Recovery and Perioperative Quality Initiative-4 joint consensus statement on persistent postoperative opioid use. Anesth. Analg. 2019; 129: 543–52.
31. Calkins TE, Hannan CP, Nam D, Gerlinger TL, Sporer SM, Della Valle CJ. Who is prescribing opioids preoperatively? A survey of new patients presenting to tertiary care adult reconstruction clinics. JAAOS 2020; 28: 301–7.
32. Rajamäki TJ, Puolakka PA, Hietaharju A, Moilanen T, Jämsen E. Use of prescription analgesic drugs before and after hip or knee replacement in patients with osteoarthritis. *BMC Musculoskelet. Disord.* 2019; **20**: 427.

33. Pryymachenko Y, Wilson RA, Abbott JH, Dowsey MM, Choong PFM. Risk factors for chronic opioid use following hip and knee arthroplasty: evidence from New Zealand population data. *J. Arthroplasty* 2020; **35**: 3099–107.e14.